Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test

An experimental Satsuma Pharmaceuticals treatment for acute migraine has failed a late-stage clinical trial, dealing a setback to the company’s plans to offer another therapeutic option to the millions of people who suffer from the condition. In Phase 3 results released Thursday, South San Francisco-based Satusuma (NASDAQ: STSA) reported that preliminary data showed both doses […]

Click to view original post